Pushing back on the concept that there can only be one victor among branded obesity drugmakers, Novo Nordisk CEO Mike Doustdar thinks that investors aren’t seeing the whole picture.
As the massive market for GLP-1 weight loss drugs continues to come into its own, patients are just now discovering their preferences, and the appetite for differentiation will likely increase as more drugs are approved in the indication, Doustdar told Reuters in an interview published Thursday.
While investors have largely taken the perspective that Novo and its chief metabolic rival Eli Lilly are playing a “zero-sum game,” there will likely be room for many players who can successfully set their obesity offerings apart in the future, Doustdar suggested.
The CEO tied that vision back to Novo’s insulin business, which could serve as a potential template for eventual GLP-1 differentiation, explaining that the company successfully promotes 12 different insulin brands, which “all reduce sugar, but they do also different things.”
In much the same way, “GLP-1s all reduce weight, but they all do different things," Doustdar said.
Dousdtar’s thesis has already been born out in part this year through the successful launch of Novo’s Wegovy pill. After getting a roughly three-month head start over the launch of Lilly’s competing obesity oral Foundayo—itself a novel molecule unrelated to the company’s injectable Mounjaro and Zepbound—Novo has appeared to maintain a substantial sales lead over Lilly’s pill, marking a reversal of the market dynamics playing out between the companies’ injectable Wegovy and Zepbound.
In its second-quarter report earlier this month, Novo noted that the Wegovy pill had reached more than 5 million patients since its Jan. 5 launch, with total weekly prescriptions for the week ending July 17 coming in above 265,000.
Novo attributed some $500 million in sales for the period to the Wegovy pill, which chipped in toward an overall obesity gain of 16% to total Q2 sales of 23.15 billion Danish kroner (roughly $3.6 billion).
Meanwhile, despite Lilly continuing to lead across the U.S. obesity market overall, second-quarter results on the launch of its oral obesity medication Foundayo have “disappointed,” Leerink Partners analyst David Risinger wrote in an early August note to clients.
While Lilly execs are guiding toward an “inflection point” in the pill’s growth, Foundayo’s $98 million haul in Q2 was well below the performance charted by oral Wegovy.
But perhaps more importantly, both companies’ tracking of prescription stats suggest that the launch of daily pills for obesity is adding new patients to the GLP-1 class—rather than simply cannibalizing sales of older injectable options—bolstering the idea that a wider obesity armamentarium will meaningfully increase the prescribing pool.
Looking further afield, both companies have several next-generation metabolic candidates in the hopper, and a slate of other mid- and late-stage obesity hopefuls are now in the works by pharma juggernauts like Amgen, Roche, Pfizer and AstraZeneca, to name just a few.
At the recent American Diabetes Association 2026 Scientific Sessions in New Orleans, the notion of differentiation on metrics like tolerability and potential patient desire for different magnitudes of weight loss—not to mention the ability of assets to tackle various health complications of obesity—was a popular topic of conversation as companies presented dueling datasets on their candidates.
Speaking to Fierce in an interview at ADA 2026, Doustdar highlighted ways in which Novo has already adopted this differentiation mindset with strategies like its “beyond weight” messaging for Wegovy, highlighting the drug’s unique cardiovascular risk reduction bona fides.
Now, the conversation is changing again, and seemingly for the better, per the CEO.
“For the first time, I’m hearing people not talk about a single digit number on weight loss effect, but a combination of things that a patient wants,” Doustdar told Fierce back in June. “Better tolerability, maybe a pill instead of an injection, maybe the quality of the weight loss is the issue—all of those things that we started spending billions of dollars in, and maybe initially did not see the return, I think was the right thing.”